Amélie Guiho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amélie Guiho has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Amir Khammari
Department of Dermatology, CHU Nantes, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, Nantes University, Nantes, France
1 shared publication - Catherine Rabu
CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
1 shared publication - Corine Bertolotto
University Cote d’Azur, Nice, France
1 shared publication - Emilie Dupré
INCIT, INSERM 1302, Labex IGO, Universitéd’Angers, Nantes Université
1 shared publication - François Lang
INCIT, INSERM 1302, Labex IGO, Universitéd’Angers, Nantes Université
1 shared publication - Gaëlle Quéreux
Centre Hospitalier Universitaire de Nantes 14
1 shared publication
Latest Publications
- Open Access
- 2 August 2025
- Published by Taylor & Francis in OncoImmunology
- Vol. 14 (1) , 2538684
Systematic identification of lincRNA-derived immunogenic peptides in melanoma
The search for reliable shared tumor-specific antigens (TSAs) to improve cancer immunotherapy is on-going. The so-called non-coding regions of the genome have recently been shown to give rise to immunogenic peptides, including the melanoma-specific antigen MELOE-1 which is translated from the long intergenic non-coding RNA (lincRNA) meloe in an IRES-dependent manner. Here, we present a strategy to systematically identify tumor-specific antigens produced by ORFs within lincRNAs with IRES-like upstream structures. We provide evidence suggesting that in the melanocytic lineage a significant proportion of the selected lincRNAs can produce immunogenic peptides. T cell repertoires against some of these peptides were found in peripheral blood mononuclear cells (PBMCs) from healthy donors and melanoma patients, and in tumor-infiltrating lymphocytes (TILs) from metastatic melanoma patients. Finally, CD8+ T cell lines from melanoma patients specific for three of the characterized HLA-A *0201 epitopes could recognize melanoma cell lines, which were enhanced by reticular stress. Thus, these peptides may represent a new class of shared TSAs in melanoma and are attractive candidates for evaluation as targets for immunotherapy in preclinical studies. In addition, our selection strategy has the potential to identify new lincRNA-derived antigens in other cancers.
- 2 August 2025
- Published by Taylor & Francis in OncoImmunology
- Vol. 14 (1) , 2538684
Open AccessSystematic identification of lincRNA-derived immunogenic peptides in melanoma
The search for reliable shared tumor-specific antigens (TSAs) to improve cancer immunotherapy is on-going. The so-called non-coding regions of the genome have recently been shown to give rise to immunogenic peptides, including the melanoma-specific antigen MELOE-1 which is translated from the long intergenic non-coding RNA (lincRNA) meloe in an IRES-dependent manner. Here, we present a strategy to systematically identify tumor-specific antigens produced by ORFs within lincRNAs with IRES-like upstream structures. We provide evidence suggesting that in the melanocytic lineage a significant proportion of the selected lincRNAs can produce immunogenic peptides. T cell repertoires against some of these peptides were found in peripheral blood mononuclear cells (PBMCs) from healthy donors and melanoma patients, and in tumor-infiltrating lymphocytes (TILs) from metastatic melanoma patients. Finally, CD8+ T cell lines from melanoma patients specific for three of the characterized HLA-A *0201 epitopes could recognize melanoma cell lines, which were enhanced by reticular stress. Thus, these peptides may represent a new class of shared TSAs in melanoma and are attractive candidates for evaluation as targets for immunotherapy in preclinical studies. In addition, our selection strategy has the potential to identify new lincRNA-derived antigens in other cancers.